SOLNA, Sweden - 13 April, 2015 - Aerocrine AB (Nasdaq Stockholm: AERO) announces that the annual report for 2014 has been published. The complete annual report can be found on the Company website. See the link below: http://www.aerocrine.com/en/Investor-relations/Latest-annual-report/ For more information about Aerocrine please contact: Scott Myers, Chief Executive Officer, Aerocrine AB, Phone: +1 970 368 0336 Marshall Woodworth, Chief Financial Officer, Aerocrine AB: +1 919 749 8748 or +46 709 695 219 About Aerocrine Aerocrine AB is a medical products company focused on improved management and care of patients with inflammatory airway diseases such as Asthma. Within this sector, Aerocrine is the world leader. Aerocrine markets NIOX MINO® and NIOX VERO®, which enables fast and reliable point-of-care measurement of airway inflammation. These products play a critical role in more effective diagnosis, treatment and follow-up of patients affected with inflammatory airway diseases. Aerocrine is based in Sweden with subsidiaries in the US, Germany, Switzerland and the UK. Aerocrine shares have been listed on the Stockholm Stock Exchange since 2007 (AERO-B.ST). For more information please visit www.aerocrine.com and www.niox.com. +-----------------------------------------------------------------------------+ |Aerocrine is required to disclose the information provided herein pursuant to| |the Financial Instruments Trading Act. The information was submitted for | |publication at 08:00 am on April 13, 2015. | +-----------------------------------------------------------------------------+
Aerocrine publishes annual report for 2014
| Source: Aerocrine AB
Attachments
